Spark Therapeutics to Participate in Multiple Conferences in October
- Federico Mingozzi, Ph.D., chief scientific officer, will present on “SPK-9001 – an Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B” on
Thursday, Oct. 19 , at2:10 p.m. CET
Additionally, company management will present at the following investor conferences:
Chardan Gene Therapy Conference onTuesday, Oct. 10 , at11:40 a.m. EDT , at theWestin Grand Central inNew York - Jefferies Gene Technology Investor Summit on
Thursday, Oct. 12 , at9:00 a.m. EDT , at theWestin Grand Central inNew York
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. Spark Therapeutics has ongoing clinical trials investigating gene therapies in hemophilia A and B. SPK-8011 is in an ongoing, dose-escalation Phase 1/2 clinical trial as a potential one-time therapy for hemophilia A. The company retains full global commercialization rights to SPK-8011. SPK-9001 is in a Phase 1/2 clinical trial for hemophilia B and is being developed in collaboration with Pfizer. It has received both breakthrough therapy and orphan product designations from the Food and Drug Administration (
Investor Contact: | Media Contact: | |
Ryan Asay | Monique da Silva | |
Ryan.asay@sparktx.com | Monique.dasilva@sparktx.com | |
(215) 239-6424 | (215) 282-7470 |